Literature DB >> 6980215

Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity.

T Noto, S Miyakawa, H Oishi, H Endo, H Okazaki.   

Abstract

Thiolactomycin is a new broad-spectrum antibiotic, active in vitro against many species of Gram-positive cocci, Enterobacteriaceae, Haemophilus, acid-fast bacteria and anaerobic bacteria. However, the activity is generally moderate and bacteriostatic in action. This antibiotic eludes cross resistance with any of the known antibacterial drugs such as ampicillin, carbenicillin or cycloserine. The effect on Gram-negative bacilli in vitro is little affected by the inoculum size, the presence of horse serum, the pH of the medium or the type of medium. When thiolactomycin was added to the assay medium, the minimum inhibitory concentration of ampicillin against inducible beta-lactamase producing strains of Staphylococcus aureus and Pseudomonas aeruginosa was reduced. Thiolactomycin inhibited the production of inducible beta-lactamase in several organisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980215     DOI: 10.7164/antibiotics.35.401

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  31 in total

1.  Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis.

Authors:  B Phetsuksiri; A R Baulard; A M Cooper; D E Minnikin; J D Douglas; G S Besra; P J Brennan
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.

Authors:  Pilho Kim; Yong-Mei Zhang; Gautham Shenoy; Quynh-Anh Nguyen; Helena I Boshoff; Ujjini H Manjunatha; Michael B Goodwin; John Lonsdale; Allen C Price; Darcie J Miller; Ken Duncan; Stephen W White; Charles O Rock; Clifton E Barry; Cynthia S Dowd
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

3.  Discovery of FabH/FabF inhibitors from natural products.

Authors:  Katherine Young; Hiranthi Jayasuriya; John G Ondeyka; Kithsiri Herath; Chaowei Zhang; Srinivas Kodali; Andrew Galgoci; Ronald Painter; Vickie Brown-Driver; Robert Yamamoto; Lynn L Silver; Yingcong Zheng; Judith I Ventura; Janet Sigmund; Sookhee Ha; Angela Basilio; Francisca Vicente; José Rubén Tormo; Fernando Pelaez; Phil Youngman; Doris Cully; John F Barrett; Dennis Schmatz; Sheo B Singh; Jun Wang
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Recent advances in the chemistry and biology of naturally occurring antibiotics.

Authors:  K C Nicolaou; Jason S Chen; David J Edmonds; Anthony A Estrada
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

5.  Overproduction of beta-ketoacyl-acyl carrier protein synthase I imparts thiolactomycin resistance to Escherichia coli K-12.

Authors:  J T Tsay; C O Rock; S Jackowski
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

Review 6.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 7.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

8.  Characterization of beta-ketoacyl-acyl carrier protein synthase III from Streptomyces glaucescens and its role in initiation of fatty acid biosynthesis.

Authors:  L Han; S Lobo; K A Reynolds
Journal:  J Bacteriol       Date:  1998-09       Impact factor: 3.490

9.  Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin.

Authors:  Carl A Machutta; Gopal R Bommineni; Sylvia R Luckner; Kanishk Kapilashrami; Bela Ruzsicska; Carlos Simmerling; Caroline Kisker; Peter J Tonge
Journal:  J Biol Chem       Date:  2009-12-16       Impact factor: 5.157

10.  Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.

Authors:  Jun Wang; Srinivas Kodali; Sang Ho Lee; Andrew Galgoci; Ronald Painter; Karen Dorso; Fred Racine; Mary Motyl; Lorraine Hernandez; Elizabeth Tinney; Steven L Colletti; Kithsiri Herath; Richard Cummings; Oscar Salazar; Ignacio González; Angela Basilio; Francisca Vicente; Olga Genilloud; Fernando Pelaez; Hiranthi Jayasuriya; Katherine Young; Doris F Cully; Sheo B Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.